Westpac Banking Corp reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,522 shares of the biopharmaceutical company’s stock after selling 2,803 shares during the quarter. Westpac Banking Corp’s holdings in Gilead Sciences were worth $6,848,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. FMR LLC boosted its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the last quarter. Seizert Capital Partners LLC boosted its stake in shares of Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Investment Centers of America Inc. boosted its stake in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at $79.02 on Friday. The stock has a market cap of $103,221.38, a P/E ratio of 9.00, a PEG ratio of -1.68 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.75 earnings per share. sell-side analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a dividend of $0.52 per share. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.63%. Gilead Sciences’s dividend payout ratio is currently 23.69%.
Several equities research analysts have issued reports on the stock. Leerink Swann raised their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Mizuho raised their target price on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. CIBC assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 5th. They issued a “market perform” rating on the stock. Finally, Bank of America decreased their target price on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $85.03.
In related news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last quarter. Insiders own 1.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Sold by Westpac Banking Corp” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/westpac-banking-corp-sells-2803-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.